Oral administration of Momordica charantia-derived extracellular vesicles alleviates ulcerative colitis through comprehensive renovation of the intestinal microenvironment.

ABSTRACT:

Background

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), accompanied by intense inflammation, oxidative stress, and intestinal microbiota dysbiosis. Current treatments using chemotherapeutic drugs or immunosuppressants have limited effectiveness and side effects. Therefore, the development of safe, effective, and multi-targeting therapies for IBD is of great importance. Momordica charantia exhibits antioxidant, anti-inflammatory, and intestinal microbiota-regulating properties, suggesting that Momordica charantia-derived extracellular vesicles (MCEVs) have the potential for UC management.

Results

We extracted MCEVs using differential centrifugation and density gradient centrifugation. The results showed that MCEVs possessed high purity, even particle size,

SUBMITTER: Gao B 

PROVIDER: S-EPMC11959773 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature